Phaseline

Targets › NOTCH3

NOTCH3 (Neurogenic locus notch homolog protein 3): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Upon ligand activation through the released notch intracellular domain (NICD), it forms a transcriptional activator complex with RBPJ/RBPSUH and activates genes of the enhancer of split locus. (UniProt, Q9UM47)

Open in Phaseline: the race on NOTCH3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImmunomeAL102
Gamma secretase inhibitor targeting Notch signaling
NOTCH1, NOTCH2, NOTCH3Phase 2DesmoidDec 2026
Michael J. Dennis, MDCB-103
Pan-NOTCH pathway inhibitor
NOTCH1, NOTCH2, NOTCH3, NOTCH4Phase 1Adenoid Cystic CarcinomaJun 2027

Conditions

Adenoid Cystic Carcinoma (1) Desmoid (1)

Modalities

small molecule (2)

Companies

Michael J. Dennis, MD (1) Immunome (1)

Related targets

NOTCH1 (2) NOTCH2 (2) NOTCH4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.